117 related articles for article (PubMed ID: 24353725)
1. The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.
Zhao YL; Yang LB; Geng XL; Zhou QL; Qin H; Yang L; Dong YZ; Zhong JJ
Pak J Med Sci; 2013 Sep; 29(5):1225-9. PubMed ID: 24353725
[TBL] [Abstract][Full Text] [Related]
2. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma.
Bai SB; Chen HX; Bao YX; Luo X; Zhong JJ
Asian Pac J Cancer Prev; 2013; 14(6):3677-80. PubMed ID: 23886164
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of DNA repair-related genes with susceptibility and prognosis of prostate cancer.
Zhang XJ; Liu P; Zhu F
Genet Mol Res; 2014 Jan; 13(2):4419-24. PubMed ID: 24615090
[TBL] [Abstract][Full Text] [Related]
5. Role of DNA repair-related gene polymorphisms in susceptibility to risk of prostate cancer.
Yang B; Chen WH; Wen XF; Liu H; Liu F
Asian Pac J Cancer Prev; 2013; 14(10):5839-42. PubMed ID: 24289586
[TBL] [Abstract][Full Text] [Related]
6. XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer.
Yuli Y; Zhe S; Xia W; Siqing L; Zhenxuan W; Yu-Hua Z; Bing S; Jun-Wei C
Pak J Med Sci; 2013 May; 29(3):762-7. PubMed ID: 24353624
[TBL] [Abstract][Full Text] [Related]
7. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.
Wang F; Zhang SD; Xu HM; Zhu JH; Hua RX; Xue WQ; Li XZ; Wang TM; He J; Jia WH
Oncotarget; 2016 Mar; 7(10):11724-32. PubMed ID: 26887052
[TBL] [Abstract][Full Text] [Related]
8. Association of
Wang XQ; Terry PD; Li Y; Zhang Y; Kou WJ; Wang MX
World J Gastroenterol; 2019 Sep; 25(34):5152-5161. PubMed ID: 31558863
[TBL] [Abstract][Full Text] [Related]
9. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
[TBL] [Abstract][Full Text] [Related]
10. Association between common polymorphisms in
Li C; Yu X; Guo D; Liu G; Zhang K; Teng Q; Lin H
Onco Targets Ther; 2018; 11():3495-3504. PubMed ID: 29950854
[TBL] [Abstract][Full Text] [Related]
11. An insight into clinical outcome of XPG polymorphisms in breast cancer.
Malik SS; Mubarik S; Masood N; Khadim MT
Mol Biol Rep; 2018 Dec; 45(6):2369-2375. PubMed ID: 30255276
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
13. [Association of XPC and XPG polymorphisms with the risk of hepatocellular carcinoma].
Li LM; Zeng XY; Ji L; Fan XJ; Li YQ; Hu XH; Qiu XQ; Yu HP
Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):271-5. PubMed ID: 20460046
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients.
Wang Y; Han Y; Weng Q; Yuan Z
Oncotarget; 2016 Oct; 7(40):65770-65781. PubMed ID: 27588464
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of Glutathione S-transferases (GSTs) on the prognosis of osteosarcoma patients treated with chemotherapy.
Teng JW; Yang ZM; Li J; Xu B
Pak J Med Sci; 2013 Sep; 29(5):1182-6. PubMed ID: 24353716
[TBL] [Abstract][Full Text] [Related]
16. Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.
Li JZ; Tian ZQ; Jiang SN; Feng T
Genet Mol Res; 2014 Apr; 13(2):3186-92. PubMed ID: 24841650
[TBL] [Abstract][Full Text] [Related]
17. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer.
Hu W; Pan J; Zhao P; Yang G; Yang S
Tumour Biol; 2014 Jun; 35(6):5561-7. PubMed ID: 24615519
[TBL] [Abstract][Full Text] [Related]
19. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.
Strom SS; Estey E; Outschoorn UM; Garcia-Manero G
Leuk Lymphoma; 2010 Apr; 51(4):598-605. PubMed ID: 20141440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
